MannKind Corporation (MNKD) was Reiterated by RBC Capital Mkts to “Underperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 0.20 from a previous price target of $0.15 . RBC Capital Mkts advised their investors in a research report released on May 10, 2016.
On the company’s financial health, MannKind Corporation reported $-0.66 EPS for the quarter, missing the analyst consensus estimate by $ -0.61 based on the information available during the earnings call on Mar 14, 2016. Analyst had a consensus of $-0.05.Analysts expectations of $ .35.During the same quarter in the previous year, the company posted $-0.09 EPS.
MannKind Corporation closed down -0.02 points or -1.48% at $1.33 with 19,62,591 shares getting traded on Friday. Post opening the session at $1.36, the shares hit an intraday low of $1.31 and an intraday high of $1.4 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on May 26, 2015, Juergen Martens (COO) purchased 20,000 shares at $4.57 per share price. According to the SEC, on Apr 27, 2015, Hakan Edstrom (President & CEO) sold 73,460 shares at $4.83 per share price. On Feb 23, 2015, David Thomson (VP & General Counsel) sold 68,662 shares at $7.19 per share price, according to the Form-4 filing with the securities and exchange commission.
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s product candidate is AFREZZA inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company’s Technosphere powders are -based on the Company’s fumaryl diketopiperazine (FDKP) which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury Connecticut facility.